an independent research zine · GHRH(1-29) clipped to the board
Sermorelin is the GHRH(1-29) fragment that prompts the pituitary's own growth hormone.
A clipped, cited reading of the literature — the upstream mechanism, the pediatric and aging trials, the regenerative frontier signals, and the line where the adult human evidence honestly stops.
The short version
Sermorelin is a lab-made copy of the first 29 amino acids of GHRH (growth hormone-releasing hormone — the signal the brain sends to switch on growth hormone). It is the shortest piece of that signal that still does the whole job. Rather than putting growth hormone into the body, it nudges the pituitary (the pea-sized gland under the brain) to make and release its own, in the natural on-off rhythm. It was once an approved children's medicine, was pulled from the US market in 2008 for business reasons, and is now made by compounding pharmacies. The research below is a digest — not advice, and nothing here is dosed or sold.
Sermorelin: The GHRH(1-29) Peptide
The sermorelin peptide is the amidated 29-amino-acid fragment of human growth hormone-releasing hormone — written GHRH(1-29), and the shortest fragment that keeps the full activity of the 44-residue parent hormone. Chemists know it as sermorelin acetate; the literature also files it under GRF(1-29) and GRF(1-29)NH2. It binds the GHRH receptor (a docking site on the surface of the pituitary's growth-hormone cells) and, through that receptor, drives the gland to secrete its own growth hormone (GH).
The single most useful thing to hold onto is upstream. Sermorelin does not supply GH. It signals the cell that makes GH. Because the signal runs through the body's own machinery, the brakes stay on: somatostatin (the opposing 'stop' hormone) and IGF-1 (the downstream growth factor that reports back to the brain) keep their feedback intact, so the natural pulsatile pattern of release is preserved [4]. An editorial in Clinical Interventions in Aging argued precisely this — that a physiologic secretagogue which keeps pulsatility and feedback may be a more physiologic route to adult growth-hormone insufficiency than supplying recombinant GH directly [4]. The receptor-and-relay detail of how sermorelin works is unpacked step by step on its own page.
What the sermorelin record actually measured
Start with the cleanest result. In a multicenter trial of prepubertal growth-hormone-deficient children, once-daily subcutaneous GHRH(1-29) lifted first-year height velocity from about 4.1 cm/year to roughly 7-8 cm/year, and did so without driving IGF-1 to excess [1]. That is the finding the molecule was approved on.
In aging research the signal is also concrete. In healthy older men (mean age 68), subcutaneous GHRH(1-29) at 0.5 mg and 1 mg twice daily for 14 days produced dose-related rises in 24-hour GH and IGF-1; after the high dose, their GH/IGF-1 parameters no longer differed from those of young men, with no change in fasting glucose [2]. Pharmacology fills in the timing: in 30 healthy men, intravenous GHRH(1-29)NH2 triggered GH release at doses as low as 0.25 mcg/kg, kept serum GH elevated for about three hours despite a short plasma half-life, and showed an intranasal bioavailability of only 3-5% [3].
The full picture, study by study, lives in the research findings. The doses each study administered, and to which species, are laid out in doses studied in the literature.
The frontier — pinned, and flagged provisional
The dealt lens here is the regenerative and oncology edge of GHRH biology, and it is genuinely interesting — provided every card stays tagged as what it is. Agonist analogs of GHRH (MR-409 and MR-502) promoted wound healing by driving the proliferation and survival of human dermal fibroblasts (the skin's repair cells) through the ERK and AKT pathways, independent of the IGF-1 receptor, and topical MR-409 sped wound closure in vivo [7]. A separate line targeted the GHRH receptor for cardiac repair after a heart attack in a preclinical model [9], and a 2023 study extended that signal into a murine model of heart failure with preserved ejection fraction [15].
The most-quoted card needs the loudest caveat. A transcriptomic drug screen across 1,018 glioma patients flagged recurrent glioma as most sensitive to sermorelin in silico — a computational drug-repurposing signal, not a clinical trial of sermorelin in cancer [8]. These are frontier clippings, pinned up to think about. Two 2025 reviews now survey the whole GHRH-analog program across cancer, regenerative medicine, and metabolic disease, and that is the right altitude to read them at [13][14]. You can follow the wound-healing and oncology signals on the research page.
Where the evidence stops — and the 'get' in the name
Anti-aging and body-composition marketing for sermorelin outpaces the rigorous long-term data. An Annals of Internal Medicine editorial put it plainly: using growth-hormone secretagogues to prevent or treat the effects of aging is not yet justified by the evidence — 'not yet ready for prime time' [5]. Because GH and IGF-1 are mitogenic (they push cells to divide), chronically raising them carries a theoretical oncologic consideration common to any GH-axis intervention [5]. And GHRH analogs are prohibited in sport under the WADA list (hormone and metabolic modulators, S2).
On the regulatory record, get the history right: sermorelin was FDA-approved as a branded US product for pediatric growth-hormone deficiency (NDA 020443), withdrawn from the market in 2008 for commercial reasons — not for safety or efficacy — and is now supplied through compounding pharmacies as a long-standing Category 1 bulk substance under FDA's interim 503A policy.
A last note on the word in the domain. Get here means acquire the literature — clip it, read it, file it. This is a reading board, not a counter. There is no storefront. Nothing here is dosed, prescribed, or sold. Bring your common questions about sermorelin; leave with the research findings.